Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Smith

Showing results (141-150 of 172) with videos related to

Pageof 18
Sort By:
The Journal of Arthroplasty|October 26, 2024
How Should Vancouver B1-Periprosthetic Fractures at the Tip of a Cemented or Uncemented Femoral Stem Be Treated?Pablo A Slullitel, Jakob Van Oldenrijk, Shang-Wen Tsai, et al.
Journal for Immunotherapy of Cancer|February 17, 2022
CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experienceM Lia Palomba, David Qualls, Sebastien Monette, et al.
Blood Cancer Discovery|October 22, 2020
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple MyelomaCarlos Fernández de Larrea, Mette Staehr, Andrea V Lopez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2019
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple MyelomaAdam R Bryant, Patrick Hilden, Sergio Giralt, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 22, 2018
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell VectorEric L Smith, Mette Staehr, Reed Masakayan, et al.
Cancer Immunology Research|May 23, 2019
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L Smith, Sham Mailankody, Mette Staehr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple MyelomaMalin Hultcrantz, Even H Rustad, Venkata Yellapantula, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2020
Prognostic Factors for Postrelapse Survival after ex Vivo CD34<sup>+</sup>-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple MyelomaAlexandra Gomez-Arteaga, Gunjan L Shah, Raymond E Baser, et al.
Journal for Immunotherapy of Cancer|July 15, 2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myelomaNina Shah, Jack Aiello, David E Avigan, et al.
Cell Reports|August 23, 2025
Integrative genomic identification of therapeutic targets for pancreatic cancerJimmy A Guo, Dennis Gong, Kyle Evans, et al.
Pageof 18

Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
The Journal of Arthroplasty|October 26, 2024
How Should Vancouver B1-Periprosthetic Fractures at the Tip of a Cemented or Uncemented Femoral Stem Be Treated?Pablo A Slullitel, Jakob Van Oldenrijk, Shang-Wen Tsai, et al.
Journal for Immunotherapy of Cancer|February 17, 2022
CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experienceM Lia Palomba, David Qualls, Sebastien Monette, et al.
Blood Cancer Discovery|October 22, 2020
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple MyelomaCarlos Fernández de Larrea, Mette Staehr, Andrea V Lopez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2019
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple MyelomaAdam R Bryant, Patrick Hilden, Sergio Giralt, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 22, 2018
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell VectorEric L Smith, Mette Staehr, Reed Masakayan, et al.
Cancer Immunology Research|May 23, 2019
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L Smith, Sham Mailankody, Mette Staehr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple MyelomaMalin Hultcrantz, Even H Rustad, Venkata Yellapantula, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2020
Prognostic Factors for Postrelapse Survival after ex Vivo CD34<sup>+</sup>-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple MyelomaAlexandra Gomez-Arteaga, Gunjan L Shah, Raymond E Baser, et al.
Journal for Immunotherapy of Cancer|July 15, 2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myelomaNina Shah, Jack Aiello, David E Avigan, et al.
Cell Reports|August 23, 2025
Integrative genomic identification of therapeutic targets for pancreatic cancerJimmy A Guo, Dennis Gong, Kyle Evans, et al.
Pageof 18